A prospective, observational, UK study to describe patient reported quality of life in relapsing remitting multiple sclerosis patients treated with Aubagio® (teriflunomide) 14 mg in a routine clinical practice. (TeriQoL) First published 05/02/2019 Last updated 14/03/2024 EU PAS number:EUPAS27883 Study Ongoing